Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

NCT01989585 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

NIH

Sponsor class

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Malignant Solid Neoplasm
Metastatic Melanoma
Unresectable Melanoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Dabrafenib
PROCEDURE: Echocardiography Test
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Multigated Acquisition Scan
BIOLOGICAL: Navitoclax
OTHER: Pharmacological Study
DRUG: Trametinib

Sponsor

National Cancer Institute (NCI)